ImmuneOncia Therapeutics, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2016-09-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.immuneoncia.com
A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
Phase 2
Not yet recruiting
- Conditions
- TMB-HHistologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06365840
A Study of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT05276310
- Locations
- 🇰🇷
Asan Medical Center, Republic of Korea, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Phase 2
Active, not recruiting
- Conditions
- Extranodal NK/T-cell LymphomaExtranodal NK/T-cell Lymphoma, Nasal Type
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04414163
- Locations
- 🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Gwangju, Korea, Republic of
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
Phase 1
Completed
- Conditions
- Solid TumorLymphoma
- Interventions
- Biological: IMC-002
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04306224
- Locations
- 🇺🇸
Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03644056
- Locations
- 🇰🇷
ImmuneOncia, Yongin-si, Gyeonggi-do, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath